Adalat CC and Olanzapine and Fluoxetine
Determining the interaction of Adalat CC and Olanzapine and Fluoxetine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:FLUoxetine may increase the blood levels and effects of NIFEdipine. You may be more likely to experience serious side effects such as irregular heart rhythm, fluid retention, swelling, heart failure, and excessively low blood pressure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you develop dizziness or fainting; sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration of fluoxetine with calcium channel blockers may increase their plasma concentrations and the risk of side effects. The mechanism is reduced clearance of the calcium channel blocker due to inhibition of CYP450 3A4-mediated metabolism by fluoxetine. Reports exist for nifedipine, nimodipine, and verapamil. Theoretically, the interaction may also occur with other calcium channel blockers that are CYP450 3A4 substrates.
MANAGEMENT: Monitoring of clinical response and tolerance, including blood pressure, is recommended if fluoxetine is used in combination with calcium channel blockers that are metabolized by CYP450 3A4. Dose reductions may be considered, if necessary. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.
- "Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- "Product Information. Adalat (nifedipine)." Bayer, West Haven, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: n.a.
Generic Name: fluoxetine / olanzapine
Brand name: Symbyax
Synonyms: Fluoxetine and olanzapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Adalat CC-Olanzapine and Fluoxetine Capsules
- Adalat CC-Olanzapine Extended-Release Injection
- Adalat CC-Olanzapine injection
- Adalat CC-Olanzapine Intramuscular
- Adalat CC-Olanzapine Orally Disintegrating Tablets
- Adalat CC-Olanzapine Tablets
- Olanzapine and Fluoxetine-Adalimumab
- Olanzapine and Fluoxetine-Adalimumab Prefilled Pens and Syringes
- Olanzapine and Fluoxetine-Adalimumab Subcutaneous
- Olanzapine and Fluoxetine-Adalimumab Vials
- Olanzapine and Fluoxetine-Adalimumab-adbm Subcutaneous
- Olanzapine and Fluoxetine-Adalimumab-atto Subcutaneous